[Source: Vaccines, full page: (LINK). Abstract, edited.]
A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
by Sarah Sebastian 1,2,†, Amy Flaxman 1,† , Kuan M. Cha 1, Marta Ulaszewska 1, Ciaran Gilbride 1, Hannah Sharpe 1 , Edward Wright 3 , Alexandra J. Spencer 1, Stuart Dowall 4, Roger Hewson 4, Sarah Gilbert 1 and Teresa Lambe 1,*
1 Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; 2 Current address: Vaccitech Ltd., Oxford Science Park, Oxford OX4 4GE, UK; 3 School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK; 4 Public Health England, Porton Down, Salisbury, Wiltshire SP4 0JG, UK
*Author to whom correspondence should be addressed.
†These authors contributed equally to this work.
Vaccines 2020, 8(2), 241; https://doi.org/10.3390/vaccines8020241 (registering DOI)
Received: 6 April 2020 / Revised: 18 May 2020 / Accepted: 19 May 2020 / Published: 21 May 2020
(This article belongs to the Special Issue Vaccines for Ebola Virus and Related Diseases)
In the infectious diseases field, protective immunity against individual virus species or strains does not always confer cross-reactive immunity to closely related viruses, leaving individuals susceptible to disease after exposure to related virus species. This is a significant hurdle in the field of vaccine development, in which broadly protective vaccines represent an unmet need. This is particularly evident for filoviruses, as there are multiple family members that can cause lethal haemorrhagic fever, including Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. In an attempt to address this need, both pre-clinical and clinical studies previously used mixed or co-administered monovalent vaccines to prevent filovirus mediated disease. However, these multi-vaccine and multi-dose vaccination regimens do not represent a practical immunisation scheme when considering the target endemic areas. We describe here the development of a single multi-pathogen filovirus vaccine candidate based on a replication-deficient simian adenoviral vector. Our vaccine candidate encodes three different filovirus glycoproteins in one vector and induces strong cellular and humoral immunity to all three viral glycoproteins after a single vaccination. Crucially, it was found to be protective in a stringent Zaire ebolavirus challenge in guinea pigs in a one-shot vaccination regimen. This trivalent filovirus vaccine offers a tenable vaccine product that could be rapidly translated to the clinic to prevent filovirus-mediated viral haemorrhagic fever.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Sebastian, S.; Flaxman, A.; Cha, K.M.; Ulaszewska, M.; Gilbride, C.; Sharpe, H.; Wright, E.; Spencer, A.J.; Dowall, S.; Hewson, R.; Gilbert, S.; Lambe, T. A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. Vaccines 2020, 8, 241.
Keywords: Ebola; Marburg virus; Sudan virus; Filovirus; Vaccines.